All In Biotech

Drug Trial Radar · NCT06035497

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

83

Planned (sponsor's estimate)

Start

Nov 20, 2023

Primary completion

Aug 11, 2026

Study completion Oct 10, 2030

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Sep 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).

Conditions

  • Relapsed or Refractory T-cell Lymphomas

Interventions

  • BMS-986369Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs)Time frame: Up to 5 weeks after last dose of treatment
  2. Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to 5 weeks after last dose of treatment
  3. Number of participants with Dose-Limiting Toxicity (DLT)Time frame: Up to 28 days after first dose
  4. Number of participants with laboratory abnormalitiesTime frame: Up to 5 weeks after last dose of treatment
  5. Number of participants with vital sign abnormalitiesTime frame: Up to 5 weeks after last dose of treatment
  6. Number of participants with Electrocardiogram (ECG) abnormalitiesTime frame: Up to 5 weeks after last dose of treatment
  7. Eastern Cooperative Oncology Group Performance Status (ECOG PS)Time frame: Up to 5 weeks after last dose of treatment
  8. Number of participants with Left Ventricular Ejection Fraction (LVEF) assessment abnormalitiesTime frame: Up to 5 weeks after last dose of treatment
  9. Number of participants with Physical Examination (PE) abnormalitiesTime frame: Up to 5 weeks after last dose of treatment
  10. Number of participants who achieve Objective Response (OR) as assessed by central review per international consensus response criteria for ATLTime frame: Up to 2 years after last does of treatment
  11. Number of participants who achieve OR as assessed by central review per protocol-defined response criteria according to Lugano classification (Computed Tomography(CT)-based)Time frame: Up to 2 years after last dose of treatment

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0018

    Fukuoka, Japan

  • Local Institution - 0012

    Fukuoka, Japan

  • Local Institution - 0023

    Fukuoka, Japan

  • Local Institution - 0039

    Hiroshima, Japan

  • Local Institution - 0025

    Hiroshima, Japan

  • Local Institution - 0015

    Kagoshima, Japan

  • Local Institution - 0008

    Kagoshima, Japan

  • Local Institution - 0035

    Kumamoto, Japan

  • Local Institution - 0006

    Kumamoto, Japan

  • Local Institution - 0027

    Kyoto, Japan

  • Local Institution - 0022

    Mitaka, Japan

  • Local Institution - 0038

    Miyazaki, Japan

  • Local Institution - 0030

    Nagasaki, Japan

  • Local Institution - 0020

    Ōita, Japan

  • Local Institution - 0007

    Okayama, Japan

  • Local Institution - 0042

    Okinawa, Japan

  • Local Institution - 0010

    Osaka, Japan

  • Local Institution - 0034

    Osaka, Japan

  • Local Institution - 0031

    Anjo-shi, Aichi-ken, Japan

  • Local Institution - 0011

    Nagoya, Aichi-ken, Japan

  • Local Institution - 0024

    Toyohashi, Aichi-ken, Japan

  • Local Institution - 0017

    Kamogawa, Chiba, Japan

  • Local Institution - 0002

    Kashiwa, Chiba, Japan

  • Local Institution - 0037

    Narita, Chiba, Japan

  • Local Institution - 0016

    Iizuka, Fukuoka, Japan

  • Local Institution - 0041

    Kitakyushu-shi, Fukuoka, Japan

  • Local Institution - 0036

    Sapporo, Hokkaido, Japan

  • Local Institution - 0032

    Amagasaki, Hyōgo, Japan

  • Local Institution - 0033

    Kobe, Hyōgo, Japan

  • Local Institution - 0004

    Isehara, Kanagawa, Japan

  • Local Institution - 0013

    Yokosuka, Kanagawa, Japan

  • Local Institution - 0001

    Sendai, Miyagi, Japan

  • Local Institution - 0019

    Ōmura, Nagasaki, Japan

  • Local Institution - 0028

    Sasebo, Nagasaki, Japan

  • Local Institution - 0005

    Ōsaka-sayama, Osaka, Japan

  • Local Institution - 0009

    Hidaka, Saitama, Japan

  • Local Institution - 0003

    Chuo-ku, Tokyo, Japan

  • Local Institution - 0040

    Koto, Tokyo, Japan

  • Local Institution - 0026

    Minato-ku, Tokyo, Japan

  • Local Institution - 0029

    tabashi City, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.